World Investment Advisors Takes $674,000 Position in Halozyme Therapeutics, Inc. $HALO

World Investment Advisors bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, Holdings Channel reports. The institutional investor bought 10,014 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC boosted its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the period. Harbour Investments Inc. lifted its holdings in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares during the period. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $70,000. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total value of $690,700.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,030,564.60. The trade was a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 93,250 shares of company stock worth $6,299,746. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $68.99 on Tuesday. The firm has a market cap of $8.18 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company’s 50-day moving average price is $68.06 and its two-hundred day moving average price is $68.66.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the business posted $1.11 earnings per share. The company’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HALO. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.